Ancient ‘Dragon Man' DNA reveals mysterious human relative
It all started with a 146,000-year-old skull found by a labourer in the northern Chinese city of Harbin in 1933.
The man left his treasure at the bottom of a well, where it remained hidden until his family uncovered the fossil in 2018 and donated it to science.
Experts initially failed to match the cranium with any known prehistoric human species.
In 2021, they dubbed the discovery Homo longi or 'Dragon Man', a name derived from from Heilongjiang, or Black Dragon River, the province where the it was found.
Now, scientists have managed to extract genetic material and proteins by scrapping tooth plaque from the fossil's mouth, an unusual technique that proved successful.
The findings of the research were published in Cell and Science
Analysis confirmed the skull belongs to the Denisovans, an extinct species of archaic human beings found across Asia.
The species was first identified in 2010 thanks to DNA tests on small, fossilised bone fragments, but no complete Denisovan skull had ever been found.
Related
4,000-year-old tablets found in Iraq reveal ancient red tape
Archaeologists discover oldest section of China's Great Wall, dating back nearly 3,000 years
The new discovery will make it easier for experts to identify further Denisovan fossils and seen the species finally assigned a scientific name. The new research might also give clues regarding the species' appearance.
The Harbin skull is large, with strong and low brow ridges, similar to Neanderthals and modern humans.
Qiaomei Fu, a professor at the Institute of Paleontology and Palaeoanthropology in Beijing which led the new research wrote: "the finding that the human DNA of the Harbin specimen is better preserved in the dental calculus than in the dense bones, including the petrous bone, suggests that dental calculus may be a more valuable source for investigating DNA in Middle Pleistocene hominins."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 hours ago
- Forbes
A New Chapter For Diabetes—and Regenerative Medicine
For decades, the ambitious goal of regenerative medicine has been to replace damaged or lost tissues with healthy, functioning ones. Nowhere is this objective more compelling—or challenging—than in type 1 diabetes. Countless research efforts over the years have sought to restore these cells. Breakthroughs in cell engineering and transplantation are beginning to overcome long-standing roadblocks, and these recent advances are a significant achievement for regenerative medicine as a whole. For millions living with the constant demands and worries of type 1 diabetes, this is more than promising data. It's a moment that hints at a world where glucose monitors and needles might finally become relics of the past. With this, a life free from the daily burdens of diabetes suddenly feels not just possible, but Is Type 1 Diabetes? Type 1 diabetes is a chronic autoimmune disorder defined by the immune system's destruction of insulin-producing beta cells in the pancreas. Insulin is the hormone responsible for moving glucose from the bloodstream into the body's cells for energy. Without it, blood sugar rises to dangerous levels. Over time, it can damage virtually every organ. Most people diagnosed are children or young adults, and living with type 1 diabetes requires ongoing vigilance: regular blood glucose testing, carefully calibrated insulin administration, and persistent risk of life-threatening hypoglycemia. To survive, people with type 1 diabetes must monitor their blood sugar levels constantly. They frequently perform fingerstick tests throughout the day to check their blood glucose levels. Also, they must adjust their diet, exercise routine, and daily schedule to accommodate frequent insulin injections or an insulin pump. Despite advances in technology, keeping blood glucose within a safe range remains challenging, and the risk of life-threatening 'hypoglycemic' episodes—when blood sugar drops too low—is Stem Cell Therapy: Replacing What's Lost This is where the new therapies come into play. They go straight to the heart of the problem: the loss of the body's own insulin-producing cells. Instead of requiring patients to rely on lifelong injections, the focus is now on developing stem cells grown in controlled laboratory environments. These stem cells are engineered to become fully functional islet cells. These are the very clusters that regulate blood sugar in a healthy pancreas. The "off-the-shelf" nature of these cells is crucial. Earlier islet transplant procedures relied on donated organs, which are rare, variable in quality, and subject to lengthy waitlists. The engineered cells, on the other hand, are produced in large quantities. Also, they can be made available as needed. When infused, typically into the liver, these new cells integrate and begin responding to blood sugar levels in real time, releasing insulin as needed. In essence, the therapy is designed to restore the natural balance lost due to the disease. The promise of this approach is already becoming a the Latest Study The most recent results in the development of stem cell–derived therapies for type 1 diabetes stem from a clinical trial conducted by Vertex Pharmaceuticals. This study enrolled patients with established, severe type 1 diabetes. This is a group for whom current treatments often fail to prevent sudden and dangerous drops in blood sugar. Each patient in the trial received a single infusion of lab-grown islet cells, now referred to as zimislecel. To translate the science: the stem cells are first turned into insulin-producing islet cells in the lab. These are then infused into the patient's liver, not the pancreas. If successful, they begin sensing blood sugar levels and releasing insulin as needed, just like a healthy pancreas would. Think of this as swapping out a faulty part with a working one, rather than relying on external fixes. The results over twelve months were consistent and dramatic. All participants in the study were found to be producing their own insulin again. This was confirmed by checking bloodwork to verify that the islet cells were now active. Therefore, the transplanted cells integrated well, and the patients' bodies were able to produce insulin naturally for the first time in years. Even more remarkably, ten of these individuals were able to discontinue daily insulin injections entirely. Every participant met or surpassed the American Diabetes Association's stringent targets for glycemic control. Notably, none suffered severe hypoglycemic This Matters: The Science and Its Impact These results represent a shift in the care landscape for type 1 diabetes. Previous attempts at islet cell replacement used donor cells, which were in very limited supply. By creating islets from universal stem cells, this therapy can be scaled up. It brings the possibility of universal therapies with consistent quality and availability. This offers real hope to millions worldwide. It also signals a foundational advance in regenerative medicine itself. Demonstrating that we can produce, transplant, and integrate functional cell populations to cure a chronic, complex condition illustrates the practical power of stem cell technology. The methodology used here is already being adapted for other therapeutic targets: engineered heart muscle for cardiac repair, retinal cells for vision restoration, and dopaminergic neurons for Parkinson's disease. It establishes a blueprint for tackling similar disorders and builds a bridge from bench research to real-world clinical impact. These advances, however, are not without their complexities. Because the transplanted islet cells are not the patient's own, recipients currently require immunosuppressive medications to prevent rejection—a challenge shared by all current forms of tissue and organ transplantation. Although initial safety profiles are encouraging and side effects manageable, ongoing studies are exploring methods to reduce or eliminate immune suppression, such as gene editing and immune cloaking Road Ahead: What's Next? The achievements described here are far more than incremental progress in diabetes care. They represent proof-of-concept for the broad ambitions of regenerative medicine: restoring lost tissue function, curing chronic diseases, and making transformative treatments widely accessible. As these strategies mature and diversify, their impact will almost certainly extend well beyond any single disease. They offer a pathway to fundamentally change how we approach a broad spectrum of degenerative and autoimmune conditions. The future of regenerative medicine, once hypothetical and distant, now approaches with real hope for curing—not simply managing—a host of devastating chronic conditions.
Yahoo
2 hours ago
- Yahoo
Phonon interference hits new heights, promising leaps in quantum and energy tech
Researchers at Rice University and their collaborators have achieved a groundbreaking demonstration of strong interference between phonons, the quantum units of vibrations that carry heat and sound within materials. Their discovery shows interference two orders of magnitude greater than any previously observed, opening new possibilities for quantum sensing and computing technologies. This phenomenon, known as Fano resonance, occurs when two phonons with different frequency distributions interfere with each other, producing distinctive patterns of amplification or cancellation—similar to overlapping ripples on a pond. 'While this phenomenon is well-studied for particles like electrons and photons, interference between phonons has been much less explored,' said Kunyan Zhang, a former postdoctoral researcher at Rice and first author on the study. 'That is a missed opportunity, since phonons can maintain their wave behavior for a long time, making them promising for stable, high-performance devices.' Phonons in quantum spotlight By proving phonons can be harnessed as effectively as electrons or light, this discovery opens the door to a new generation of phonon-based technologies. The researchers achieved their results by placing a two-dimensional (2D) metal layer atop a silicon carbide substrate using a method called confinement heteroepitaxy. They intercalated just a few layers of silver atoms between graphene and silicon carbide, creating a tightly bound interface with unique quantum properties. 'The 2D metal triggers and strengthens the interference between different vibrational modes in silicon carbide, reaching record levels,' Zhang explained. The team used Raman spectroscopy, a technique that measures vibrational modes, to study how phonons interfere. The resulting spectra displayed sharply asymmetric shapes and, in some cases, full dips forming antiresonance patterns, signatures of intense interference. The phenomenon was highly sensitive to the precise nature of the silicon carbide surface, with three different surface terminations each producing distinct Raman line shapes. Vibrational signals unlock secrets Remarkably, the presence of even a single dye molecule on the surface caused dramatic changes in the spectral line shape. 'This interference is so sensitive that it can detect the presence of a single molecule,' Zhang noted. 'It enables label-free single-molecule detection with a simple and scalable setup. Our results open up a new path for using phonons in quantum sensing and next-generation molecular detection.' The study also confirmed that the interference arises purely from phonon interactions rather than electrons, marking a rare example of phonon-only quantum interference. This effect appears only in the special 2D metal/silicon carbide system studied and does not exist in bulk metals due to unique transition pathways and surface configurations created by the atomically thin metal layer. Looking ahead, researchers are exploring other 2D metals, like gallium or indium, to replicate and customize this effect. 'Compared to conventional sensors, our method offers high sensitivity without the need for special chemical labels or complicated device setup,' said Shengxi Huang, associate professor at Rice and corresponding author on the study. 'This phonon-based approach not only advances molecular sensing but also opens up exciting possibilities in energy harvesting, thermal management and quantum technologies, where controlling vibrations is key.' Supported by the National Science Foundation, Air Force Office of Scientific Research, Welch Foundation, and University of North Texas, the study has been published in the journal Science Advances. Solve the daily Crossword
Medscape
4 hours ago
- Medscape
Growth Charts for Twins Improve Perinatal Risk Prediction
TOPLINE: New customised growth charts for twins (GROW-T), adjusted for maternal characteristics, more accurately predicted a small-for-gestational age (SGA)-associated risk for adverse perinatal outcomes than charts for singletons (GROW-S). METHODOLOGY: Researchers developed customised growth charts for twin pregnancies and compared them with singleton charts to evaluate their ability to identify SGA twins who are at an increased risk for adverse perinatal outcomes. They evaluated 8457 twin pregnancies (16,914 foetuses) from 127 NHS hospitals in the UK from January 2015 to February 2025, representing approximately two thirds of all NHS units. A mixed-effects linear regression analysis was performed to determine pregnancy-specific optimal weights at 37 weeks. Researchers compared GROW-T with GROW-S by calculating rates of the SGA-associated risk for stillbirth and adverse neonatal outcomes, such as the need for resuscitation, an Apgar score < 7 at 5 minutes, admission to the NICU, or neonatal death, using generalised estimating equations. TAKEAWAY: At 37 weeks, the average optimal weight of a twin was 389 g less than that of an equivalent singleton foetus. By pregnancy, 24.6% vs 64.9% of twins were classified as those with SGA (< 10th centile) according to GROW-T vs GROW-S; when analysed by individual foetuses, 13.8% vs 44.4% of twins were classified as those with SGA according to GROW-T vs GROW-S. Twins designated as SGA on the basis of GROW-T (odds ratio [OR], 7.2; 95% CI, 4.8-10.8) had a higher risk for stillbirth than those designated as SGA on the basis of GROW-S (OR, 2.8; 95% CI, 1.9-4.1). Twins classified as those with SGA on the basis of GROW-T had an increased need for resuscitation (OR, 1.3; 95% CI, 1.1-1.7), a lower Apgar score (< 7) at 5 minutes (OR, 1.8; 95% CI, 1.2-2.6), higher NICU admissions (OR, 1.3; 95% CI, 1.0-1.6), and an increased risk for neonatal death (OR, 5.4; 95% CI, 1.3-23.5). IN PRACTICE: "Our results add to the increasing evidence for adoption of twin specific charts," the authors wrote. "While adoption of twin specific charts is timely, implementation ought to be accompanied by evaluation in practice to monitor safety in different health service environments," they added. SOURCE: This study was led by Jason Gardosi, MD, Perinatal Institute, Birmingham, England, and was published online on August 01, 2025, in the American Journal of Obstetrics & Gynecology. LIMITATIONS: Ultrasound estimates of foetal weight in twins can be systematically overestimated, potentially affecting the accuracy of growth assessments. Chorionicity was not reported in the study cohort; however, the difference between growth curves of monochorionic and dichorionic twins was considered too small to be clinically relevant. DISCLOSURES: No funding information was provided for the study. All authors reported being employees of the Perinatal Institute, Birmingham, England. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
